News | July 25, 2012

Technology Allows More Atlanta Patients to Self-Manage Their Heart Disease

Data on how Emmi Solutions’ technology improves patient flow, care and reimbursement to be showcased at AHA’s 2012 Leadership Summit

July 25, 2012 — Grady Memorial Hospital has standardized and improved patient education and reduced by 75 percent the amount of time staff spend educating new patients about warfarin by implementing Emmi Solutions’ interactive multimedia program in its Coumadin clinic. This has allowed Grady, the largest hospital in Georgia and the public hospital for Atlanta, to add 138 patient appointment slots per month to better meet the needs of a growing heart disease population. This study was selected as a poster display at the 20thAnnual Health Forum and the American Hospital Association Leadership Summit to be held July 19 to July 21 in San Francisco.

Grady previously had to limit the number of new patient visits to its Coumadin clinic per day due to the length of time — nearly 90 minutes — required to help each new patient understand their condition and self-management responsibilities. This could delay the date of the first visit for new patients.

Despite Grady’s heavily underserved, older patient population – which includes many computer novices – 100 percent of patients participate in the interactive multimedia program during their clinic visit. The program educates them about their condition and treatment, and engages them to actively self-manage their care.

Grady Health System is one of the largest public health systems in the United States. Grady consists of the 953-bed Grady Memorial Hospital, six neighborhood health centers, Crestview Health & Rehabilitation Center, and Children's Healthcare of Atlanta at Hughes Spalding, which is operated as a Children's affiliate.

Emmi’s proprietary interactive communication methodology – which incorporates graphics, text and spoken words – delivers actionable health information to patients at key moments across the continuum of care. It has been demonstrated to help healthcare providers reduce costs, increase revenue and improve outcomes by engaging and empowering patients. The platform allows providers to track the delivery and consumption of information to measure the clinical and financial impact of patient engagement and meet regulatory guidelines. The web-based platform requires no installation or maintenance and can be used in stand-alone mode or fully integrated into existing systems.

For more information: www.gradyhealth.org

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init